Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial.
The Lancet Oncology.
Times cited: 400
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.
New England Journal of Medicine.
Times cited: 1519